Invited Commentary

Commentary on "No to Greed"

Authors: Daniel P. Hunt, MD

Abstract

The perspective “No to Greed” by Terpening in this issue of the Southern Medical Journal provides an appraisal on the controversy surrounding the cost of sofosbuvir as a potentially curative treatment for hepatitis C virus (HCV).1 Sofosbuvir represents a substantial advance in the treatment of HCV. The drug is taken orally, is generally well tolerated, and in clinical trials results in “cure” of this chronic disease in a high percentage of patients.2 These advantages are already widely known by the public and physicians. HCV is contributing to increasing hospitalizations for chronic liver disease and will likely intensify unless effective treatment is broadly applied.3

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Terpening C. No to greed. South Med J 2015;108:63-64.
 
2. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014;348:g3308.
 
3. Xu F, Tong X, Leidner AJ. Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Aff (Millwood) 2014;33:1728-1735.
 
4. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA 2014;312:593-594.
 
5. San Miguel R, Gimeno-Ballester V, Blázquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2014 October 13. [Epub ahead of print] .
 
6. Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2014 September 15. [Epub ahead of print] .
 
7. Liu S, Watcha D, Holodniy M, et al. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in u.s. Incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 2014;161:546-553.
 
8. Senior M. Sovaldi makes blockbuster history, ignites drug pricing unrest. Nat Biotechnol 2014;32:501-502.